GlassScriptPhysician profile
Samantha A Mclean
NPI 1841815701
$6,725.06
in general payments reported to CMS, 2019-2025
44 companies · $3,378 in 2025
The $3,378 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $602 · 2023: $1,232 · 2024: $1,196 · 2025: $3,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,683 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,682.65 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $632.48 | 2024-2025 | Auvelity, Symbravo |
| Janssen Biotech, INC. | $561.53 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $536.20 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $433.86 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $420.60 | 2022-2025 | Airsupra, Breztri, Fasenra |
| Astellas Pharma US INC | $396.12 | 2022-2024 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $354.34 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $287.65 | 2025 | |
| Janssen Pharmaceuticals, INC | $279.58 | 2022-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $262.93 | 2025 | Cobenfy |
| Glaxosmithkline, LLC. | $243.44 | 2023-2024 | Arexvy |
| Vanda Pharmaceuticals INC. | $231.36 | 2025 | Fanapt, Hetlioz |
| Sage Therapeutics, LLC | $204.30 | 2024-2025 | Zurzuvae |
| Lundbeck LLC | $168.39 | 2024-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $148.48 | 2025 | Austedo Xr |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $125.00 | 2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $125.00 | 2025 | Jornay Pm |
| Grifols USA, LLC | $124.98 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.82 | 2023 | Dupixent |
| Daiichi Sankyo INC. | $117.82 | 2023-2024 | Injectafer |
| Sumitomo Pharma America, INC. | $113.06 | 2023-2024 | Myfembree |
| Silk Road Medical, INC. | $95.71 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Paratek Pharmaceuticals, INC. | $86.58 | 2025 | Nuzyra |
| Boston Scientific Corporation | $81.76 | 2025 | General - Female Sui |
| Biohaven Pharmaceutical Holding Company LTD. | $63.76 | 2022 | |
| Idorsia Pharmaceuticals US INC | $59.43 | 2022 | |
| Millicent US INC | $45.64 | 2024-2025 | Intrarosa |
| Therapeuticsmd, INC. | $41.83 | 2021-2022 | |
| Alkermes, INC. | $38.17 | 2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $34.77 | 2025 | Trintellix |
| Corium, LLC | $33.91 | 2025 | Azstarys |
| Organon LLC | $29.15 | 2024 | |
| Lilly USA, LLC | $28.34 | 2024-2025 | Zepbound |
| Pfizer INC. | $27.08 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $23.62 | 2025 | Rexulti |
| Myovant Sciences INC. | $20.19 | 2022 | |
| Hologic Sales and Service, LLC | $19.49 | 2023 | Acessa Provu System |
| Novo Nordisk INC | $18.87 | 2023 | |
| Exeltis, USA INC. | $17.63 | 2024 | Slynd |
| Tris Pharma INC | $16.46 | 2025 | Dyanavel Xr |
| Scynexis, INC. | $13.83 | 2022 | |
| Genentech USA, INC. | $13.78 | 2021 | |
| Merck Sharp & Dohme LLC | $13.78 | 2021 | |
| Evofem Biosciences, INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.